Welcome to our dedicated page for KalVista Pharmaceuticals news (Ticker: $KALV), a resource for investors and traders seeking the latest updates and insights on KalVista Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect KalVista Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of KalVista Pharmaceuticals's position in the market.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) granted ten newly-hired employees inducement options to purchase 94,000 shares of common stock on May 1, 2024. The options have an exercise price of $12.18 per share and vest over a four-year period. This action was taken in accordance with Nasdaq Listing Rule 5635(c)(4).
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced its strategic plans for fiscal year 2025, focusing on sebetralstat, an oral therapy for hereditary angioedema. The company aims to finalize regulatory filings in the US, EU, UK, and Japan for potential commercial launches in 2025-2026. KalVista plans to engage commercial partners, extend the product lifecycle, and reduce spending on non-core activities to achieve positive cash flow within a few years of commercial launch.